Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PB
Parabilis Medicines, Inc. Common Stock
PBLS
Mkt Cap
$2.81B
Volume
1.01M
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
PB
PBLS
PB
Parabilis Medicines, Inc. Common Stock
PBLS
News
·
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Mkt Cap
$3.11B
Volume
1.01M
Next Earnings
November 12th
Chart
Financials
Earnings
News
About
Insider
Filings
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., an accomplished oncology drug development leader with over 30 years of experience and two decades at Johnson & Johnson, to its Board of Directors. Dr. Tendler will continue his role as scientific advisor while joining the board to support the company's advancement of zolucatetide across multiple indications and its broader pipeline of Helicon therapeutics.
GlobeNewswire Inc. · Aug 25, 2026
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
Parabilis Medicines raised $670 million in the largest biotech IPO on record, soaring 58% on its first trading day. The company's innovative Helicon platform targets previously 'undruggable' proteins for cancer treatment. While the technology shows promise with lead candidate zolucatetide entering phase 3 trials, the company faces significant losses ($145 million last year) and remains years away from generating revenue, making it suitable only for aggressive investors willing to wait several years.
The Motley Fool · Jun 12, 2026
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Parabilis Medicines (NASDAQ: PBLS), a clinical-stage biopharmaceutical company, announced the successful closing of its upsized IPO on June 11, 2026, raising $770.5 million in gross proceeds from 38.5 million shares at $20 per share, plus an additional $75 million from a concurrent private placement with Regeneron Pharmaceuticals. The company has raised over $1.2 billion in total funding in 2026 to support development of its proprietary Helicons™ therapeutic platform targeting undruggable protein targets.
Benzinga · Jun 11, 2026
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
PB
PBLS
Parabilis Medicines, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
PBLS
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any PBLS yet.
Related Tickers
Earnings